The Trump Administration’s Attempts to Ban Gender Affirming Care for Minors Are Illegal, by Sean M. McBride and Alexander Chen

Key Takeaways

• HHS proposes Medicare/Medicaid condition banning gender‑affirming care for minors.
• Rule would force hospitals to forfeit federal payments, risking insolvency.
• Statutes 1801 and 1905(r) explicitly limit HHS from dictating medical treatments.
• Legal challenges likely to shape future scope of federal health‑care authority.

Pulse Analysis

The Trump administration’s latest regulatory push targets gender‑affirming care for minors by attaching a blanket prohibition to Medicare and Medicaid participation. While the Department cites its authority under Sections 1861(e) and 1905(a) of the Social Security Act, courts have repeatedly interpreted Section 1801 as a clear barrier to any federal directive that dictates what physicians may or may not provide. This legal backdrop, combined with the Supreme Court’s guidance on catch‑all statutory language, suggests the rule stretches statutory intent beyond permissible limits.

Beyond statutory constraints, the proposed condition collides with Medicaid’s Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit, which obligates states to cover medically necessary services for beneficiaries under 21. Gender‑affirming treatments, endorsed by major medical societies as evidence‑based interventions for gender dysphoria, fall squarely within EPSDT’s coverage criteria. By imposing a nationwide ban, HHS would not only contravene federal law but also force hospitals to violate state anti‑discrimination statutes, exposing them to legal liability and eroding the contract‑based relationship that underpins Medicare and Medicaid funding.

If the rule survives initial review, its ramifications extend far beyond trans youth care. An upheld ban would grant the executive branch a powerful tool to restrict any contested medical service—from abortion to experimental therapies—by leveraging funding conditions. Such a precedent could upend the traditional balance of power that reserves treatment decisions for states and clinicians. Consequently, litigation against the rule is poised to become a defining battle over the limits of federal authority in health‑care regulation, with stakes that could reshape the nation’s health‑policy landscape for years to come.